If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Supporters praised Gaddafi's administration for the creation of a more equal society through domestic reform. They stressed the regime's achievements in combating homelessness, ensuring access to food and safe drinking water, and to dramatic improvements in education. Supporters have also applauded achievements in medical care, praising the universal free healthcare provided under the Gaddafist administration, with diseases like cholera and typhoid being contained and life expectancy raised. Gaddafi's government's treatment of non-Arab Libyans came in for criticism from human rights activists, with native Berbers, Italian colonists, Jews, refugees, and foreign workers all facing persecution in Gaddafist Libya. Human rights groups also criticized the treatment of migrants, including asylum seekers, who passed through Gaddafi's Libya on their way to Europe. During the Civil War, various leftist groups endorsed the anti-Gaddafist rebels—but not the Western military intervention—by arguing that Gaddafi had become an ally of Western imperialism by cooperating with the war on terror and efforts to block African migration to Europe. Gaddafi was widely perceived as a terrorist, especially in the US and UK.
=== Ko–Ku === Arthur Kornberg (1918–2007). American biochemist at Stanford, who won the Nobel Prize in Chemistry (1959) for discovery of DNA polymerase. Member Natl. Acad. Sci. USA. Sir Hans Kornberg FRS (1928–2019). British biochemist at Cambridge University, known for research in microbial biochemistry. Member Natl. Acad. Sci. USA. Roger D. Kornberg (b. 1947). American biochemist at Stanford, who won the Nobel Prize in Chemistry (2006) for studies on RNA polymerase. Member Natl. Acad. Sci. USA. Sylvy Kornberg (1917–1986). American biochemist at Stanford, who worked in collaboration with Arthur Kornberg on DNA replication and polyphosphate synthesis. Thomas B. Kornberg (b. 1948). American biochemist at UC San Francisco, who works on Drosophila melanogaster development. Daniel E. Koshland Jr. (1920–2007). American biochemist at UC Berkeley, known for protein flexibility (induced fit). Member Natl. Acad. Sci. USA Douglas Koshland (b. 1953). Molecular and cellular biologist at UC Berkeley. Edwin Gerhard Krebs (1918–2009) was an American biochemist at the University of Washington, Seattle, and Nobel prizewinner, known for the study of phosphorylation/hydrolysis cycling. Sir Hans Adolf Krebs FRS (1900–1981). British biochemist at Sheffield and Oxford, known for many advances in metabolism, most notably the tricarboxylate ("Krebs") cycle. Nobel Prize in Physiology or Medicine (1953). Charles Kurland (b. 1936) Member of the Royal Swedish Academy of Sciences. Swedish biochemist at Lund University, of American origin, known for work on the tree of life.
When reporting on the masses of extrasolar planets, astronomers often discuss them in terms of multiples of Jupiter's mass (MJ = 1.9 ×1027 kg). For example, "Astronomers recently discovered a planet outside our Solar System with a mass of approximately 3 Jupiters." Furthermore, the mass of Jupiter is nearly equal to one thousandth of the mass of the Sun.
Sources: en.wikipedia.org
The endoneurium (also called endoneurial channel, endoneurial sheath, endoneurial tube, or Henle's sheath) is a layer of delicate connective tissue around the myelin sheath of each myelinated nerve fiber in the peripheral nervous system. Its component cells are called endoneurial cells. The endoneuria with their enclosed nerve fibers are bundled into groups called nerve fascicles, each fascicle within its own protective sheath called a perineurium. If sufficiently large, nerves containing multiple fascicles, each with its blood supply and fatty tissue, may be bundled within yet another sheath, the epineurium. The endoneurium contains a liquid known as endoneurial fluid, which contains little protein. In the peripheral nervous system the endoneurial fluid is notionally equivalent to cerebrospinal fluid in the central nervous system. Peripheral nerve injuries commonly release increased amounts of endoneurial fluid into surrounding tissues; these can be detected by magnetic resonance neurography, thereby assisting in locating injuries to peripheral nerves. The endoneurium runs longitudinally along the nerve fiber, but with discontinuities where septa pass inward from the innermost layer of the perineurium. It contains fine bundles of fibrous connective tissue, primarily collagen, embedded in a matrix of ground substance. This structure serves to support capillary blood vessels, arranged so as to form a network of elongated meshes.
==== Canada, United Kingdom, and Europe ==== In Canada, e-cigarettes had an estimated value of 140 million CAD in 2015. There are numerous e-cigarette retail shops in Canada. A 2014 audit of retailers in four Canadian cities found that 94% of grocery stores, convenience stores, and tobacconist shops which sold e-cigarettes sold nicotine-free varieties only, while all vape shops stocked at least one nicotine-containing product. By 2015, the e-cigarette market had only reached a twentieth of the size of the tobacco market in the UK. In the UK in 2015 the "most prominent brands of cigalikes" were owned by tobacco companies, however, with the exception of one model, all the tank types came from "non-tobacco industry companies". Yet some tobacco industry products, while using prefilled cartridges, resemble tank models. By 2023, 1 survey by the Local Data Company counted 3,573 specialist vape shops in the UK, and NIQ data cited in press reporting put value sales of vaping products in Britain at £897.4 million. Sky News similarly reported that more than 230 independent vape shops opened in 2023, citing the same Local Data Company survey. France's e-cigarette market was estimated by Groupe Xerfi to be €130 million in 2015. Additionally, France's e-liquid market was estimated at €265 million. In December 2015, there were 2,400 vape shops in France, 400 fewer than in March of the same year. Industry organization Fivape said the reduction was due to consolidation, not to reduced demand.
The government also introduced facilitation measures for international media, including visa-on-arrival arrangements for foreign journalists covering the talks and shuttle transport services between designated media area, Jinnah Convention Centre, and Serena Hotel.
=== Valuation === Theranos raised millions of dollars in its first years. In 2004, Theranos was based in a rented basement near the Stanford campus. By December 2004, the company had raised more than $6 million from investors at a valuation of $30 million. The company had about $45 million total fundraising after Series B and Series C funding in 2006. Theranos raised an additional $45 million in 2010 at a valuation of $1 billion. The company had significant news coverage starting in September 2013 after profiles in the San Francisco Business Times and The Wall Street Journal. By 2014, Theranos had raised more than $400 million with an estimated value of $9 billion. Theranos raised more than $700 million from venture capitalists and private investors, resulting in a $10 billion valuation at its peak in 2013 and 2014. In 2016, Forbes revised the estimated net worth of the company to $800 million taking into account the $724 million of capital raised. Between 2004 and 2016, the amount of available cash from investors for private equity/venture capital firms to invest in companies grew from $400 billion to $1.5 trillion. It was a period of plentiful capital available where investors were pressured to find investment targets to deploy capital on. In the Theranos case, insufficient due diligence and fraudulent business practices led to the losses for investors. In May 2017, participating shareholders provided a release of any potential claims against Theranos in exchange for shares of the company's new preferred stock.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.